CN1739678A - 一种治疗风寒湿痹症疼痛的药物及其制备方法 - Google Patents
一种治疗风寒湿痹症疼痛的药物及其制备方法 Download PDFInfo
- Publication number
- CN1739678A CN1739678A CNA2005100366945A CN200510036694A CN1739678A CN 1739678 A CN1739678 A CN 1739678A CN A2005100366945 A CNA2005100366945 A CN A2005100366945A CN 200510036694 A CN200510036694 A CN 200510036694A CN 1739678 A CN1739678 A CN 1739678A
- Authority
- CN
- China
- Prior art keywords
- radix
- wind
- group
- medicine
- kgd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 208000002193 Pain Diseases 0.000 title claims abstract description 40
- 230000036407 pain Effects 0.000 title claims abstract description 38
- 229940079593 drug Drugs 0.000 title description 27
- 238000002360 preparation method Methods 0.000 claims abstract description 8
- 239000000843 powder Substances 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 17
- 239000006187 pill Substances 0.000 claims description 14
- 239000012567 medical material Substances 0.000 claims description 8
- 241000903946 Clematidis Species 0.000 claims description 7
- 241001163443 Daphne giraldii Species 0.000 claims description 7
- 230000006837 decompression Effects 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 241000241550 Cyathula Species 0.000 claims description 2
- 241000202807 Glycyrrhiza Species 0.000 claims description 2
- 241000792914 Valeriana Species 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000000706 filtrate Substances 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims description 2
- 235000019640 taste Nutrition 0.000 claims description 2
- 235000017468 valeriana Nutrition 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 241000972155 Moschus Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 22
- 231100000862 numbness Toxicity 0.000 abstract description 8
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 230000001737 promoting effect Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 3
- 240000008918 Chaenomeles cathayensis Species 0.000 abstract 1
- 235000009810 Chaenomeles cathayensis Nutrition 0.000 abstract 1
- 241000229179 Ledebouriella Species 0.000 abstract 1
- 241000913745 Spatholobus Species 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 description 80
- 241000700159 Rattus Species 0.000 description 50
- 210000002683 foot Anatomy 0.000 description 35
- 230000008961 swelling Effects 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 201000010099 disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- 208000006820 Arthralgia Diseases 0.000 description 16
- 230000037396 body weight Effects 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 239000008280 blood Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 208000009386 Experimental Arthritis Diseases 0.000 description 12
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 10
- 230000001717 pathogenic effect Effects 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 231100000915 pathological change Toxicity 0.000 description 9
- 230000036285 pathological change Effects 0.000 description 9
- 230000001629 suppression Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 206010018691 Granuloma Diseases 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 206010030113 Oedema Diseases 0.000 description 8
- 230000003203 everyday effect Effects 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 241000700157 Rattus norvegicus Species 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 102000002322 Egg Proteins Human genes 0.000 description 5
- 108010000912 Egg Proteins Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 5
- 244000153234 Hibiscus abelmoschus Species 0.000 description 5
- 241001062009 Indigofera Species 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010003246 arthritis Diseases 0.000 description 5
- 230000004856 capillary permeability Effects 0.000 description 5
- 210000003194 forelimb Anatomy 0.000 description 5
- 210000004681 ovum Anatomy 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 229920000742 Cotton Polymers 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 240000001624 Espostoa lanata Species 0.000 description 4
- 235000009161 Espostoa lanata Nutrition 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 229930040373 Paraformaldehyde Natural products 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000002513 implantation Methods 0.000 description 4
- 229920002866 paraformaldehyde Polymers 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 208000012659 Joint disease Diseases 0.000 description 3
- 206010036030 Polyarthritis Diseases 0.000 description 3
- 210000000544 articulatio talocruralis Anatomy 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000002085 persistent effect Effects 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 208000030428 polyarticular arthritis Diseases 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 230000001047 pyretic effect Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 239000003435 antirheumatic agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001617 migratory effect Effects 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- 238000007427 paired t-test Methods 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 2
- 238000007670 refining Methods 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 238000009495 sugar coating Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 241000594182 Sarcophaga sigma Species 0.000 description 1
- 241000238370 Sepia Species 0.000 description 1
- 206010067130 Spastic diplegia Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000078 anti-malarial effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004090 etiopathogenesis Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 210000000454 fifth toe Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 108010084652 homeobox protein PITX1 Proteins 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000011337 individualized treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940029329 intrinsic factor Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量g/(kg·d) | n | 致炎后不同时间足肿胀度(Δml) | |||
6h | 12h | 8h | 4h | |||
正常组模型组祛风息痛丸低剂量组祛风息痛丸中剂量组祛风息痛丸高剂量组追风透骨丸组 | 0.260.782.341.29 | 101010101010 | 0.12±0.090.88±0.19b0.68±0.26b0.58±0.27bd(34.1)0.45±0.30bde(48.9)0.62±0.19bc(29.5) | 0.18±0.140.97±0.26b0.91±0.20b0.73±0.19bdc(24.7)0.47±0.29bdefg(51.5)0.62±0.30bdf(36.1) | 0.15±0.141.17±0.33b0.92±0.27bc(21.4)0.74±0.34bd(36.8)0.41±0.19adfh(65.0)0.58±0.27bdf(50.4) | 0.13±0.130.71±0.32b0.54±0.21b0.43±0.18bd(39.4)0.30±0.18de(57.7)0.42±0.26bd(40.8) |
组别 | 剂量g/(kg·d) | n | 致炎后不同时间足肿胀度(Δml) | |||
12d | 18d | 24d | 30d | |||
正常组模型组祛风息痛丸低剂量组祛风息痛丸中剂量组祛风息痛丸高剂量组追风透骨丸组 | 0.260.782.341.29 | 101010101010 | 0.08±0.100.62±0.19b0.52±0.18b0.42±0.14bd(32.3)0.21±0.14adfh(66.1)0.45±0.08bc(27.4) | 0.09±0.091.04±0.28b0.71±0.38bd(31.7)0.61±0.22bd(41.3)0.37±0.24adf(64.4)0.64±0.28bd(38.5) | 0.13±0.080.87±0.24b0.70±0.16b0.53±0.24bd(39.1)0.35±0.20adf(59.8)0.61±0.22bd(29.9) | 0.07±0.080.72±0.16b0.58±0.22bc(19.4)0.41±0.16bde(43.1)0.22±0.09adfh(69.4)0.50±0.14bd(30.6) |
组别 | 剂量g/(kg·d) | n | 致炎后不同时间关节病变评分 | |||
12d | 18d | 24d | 30d | |||
正常组模型组祛风息痛丸低剂量组祛风息痛丸中剂量组祛风息痛丸高剂量组追风透骨丸组 | 0.260.782.341.29 | 101010101010 | 1.6±1.04.7±1.5b4.6±1.4b4.3±1.3b2.2±1.0dfh3.2±1.8ace | 1.3±0.910.5±1.5b8.5±1.8bc6.3±2.2bdf4.4±2.2bdfg6.7±1.8bde | 1.6±0.99.2±1.3b7.7±1.6bc5.8±1.7bdf3.6±1.4bdfg5.2±1.8bdf | 1.4±0.88.3±1.9b6.0±2.0bd4.7±1.9bd3.1±1.2adfg4.9±1.8bd |
组别 | 剂量g/(kg·d) | n | 前肢红肿(%) | 尾部结节(%) | 耳部红斑(%) |
正常组模型组祛风息痛丸低剂量组祛风息痛丸中剂量组祛风息痛丸高剂量组追风透骨丸组 | 0.260.782.341.29 | 101010101010 | 0100b20d0d0d10d | 090b10d0d0d0d | 0200000 |
组别 | 剂量g/(kg·d) | n | 体重(g) | 胸腺(mg/100g体重) | 脾脏(mg/100g体重) | |
药前 | 药后 | |||||
正常组模型组祛风息痛丸低剂量组祛风息痛丸中剂量组祛风息痛丸高剂量组追风透骨丸组 | 0.260.782.341.29 | 101010101010 | 192±6190±8193±4191±6193±6193±6 | 291±11287±10293±12293±9289±12292±10 | 201±24201±31198±47195±24204±14199±22 | 239±11228±37237±32220±36242±39216±29 |
组别 | 剂量g/(kg·d) | n | 致炎后不同时间足肿胀度(Δml) | ||||||
2h | 4h | 6h | 24h | 48h | 72h | 96h | |||
对照组 | 10 | 0.63±0.13 | 0.85±0.18 | 0.87±0.11 | 0.95±0.10 | 0.83±0.12 | 0.63±0.19 | 0.46±0.16 |
祛风息痛丸低剂量组祛风息痛丸中剂量组祛风息痛丸高剂量组追风透骨丸组 | 0.260.782.341.29 | 10101010 | 0.49±0.16a(22.2)0.45±0.15b(28.6)0.34±0.14bc(46.0)0.39±0.13b(38.1) | 0.73±0.190.66±0.20a(22.4)0.61±0.19b(28.2)0.63±0.21a(25.9) | 0.77±0.120.70±0.09b(19.5)0.60±0.16bd(31.0)0.68±0.09b(21.8) | 0.78±0.16a(17.9)0.69±013b(27.4)0.65±0.23b(31.6)0.70±0.13b(26.3) | 0.72±0.120.61±0.19b(26.5)0.52±0.17bd(37.3)0.56±0.15bc(32.5) | 0.54±0.160.47±0.16a(25.4)0.37±0.18bc(41.3)0.45±0.15a(28.6) | 0.36±0.090.31±0.11a(32.6)0.27±0.11b(41.3)0.32±0.12a(30.4) |
组别 | 剂量g/(kg·d) | n | 致炎后不同时间足肿胀度(Δml) | ||||
5min | 30min | 1h | 2h | 3h | |||
对照组祛风息痛丸低剂量组 | 0.26 | 1010 | 0.35±0.270.31±0.30 | 0.74±0.330.62±0.42 | 0.72±0.230.69±0.31 | 0.59±0.410.38±0.40 | 0.25±0.220.18±0.13 |
祛风息痛丸中剂量组祛风息痛丸高剂量组追风透骨丸组 | 0.782.341.29 | 101010 | 0.25±0.300.10±0.15a(71.4)0.12±0.17a(65.7) | 0.40±0.24a(47.2)0.37±0.24b(50.0)0.40±0.22a(45.9) | 0.42±0.15bc(41.7)0.31±0.23bd(56.9)0.29±0.24bd(59.7) | 0.26±0.26a(55.9)0.12±0.19b(79.7)0.13±0.17b(78.0) | 0.12±0.100.08±0.14a(68.0)0.11±0.19 |
组别 | 剂量g/(kg·d) | n | 棉球肉芽肿重量(mg) | 抑制率(%) |
对照组祛风息痛丸低剂量组祛风息痛丸中剂量组祛风息痛丸高剂量组追风透骨丸组 | 0.260.782.341.29 | 1010101010 | 46.6±8.742.3±6.231.7±10.7bc25.6±11.8bd35.1±12.5a | 32.045.124.7 |
组别 | 剂量g/(kg·d) | n | 蓝染皮斑面积(mm2) | 抑制率(%) | 吸光度 | 抑制率(%) |
对照组祛风息痛丸低剂量组祛风息痛丸中剂量组祛风息痛丸高剂量组追风透骨丸组 | 0.260.782.341.29 | 1010101010 | 178.0±19.9166.0±29.1143.5±29.7b134.7±22.8bd151.0±25.4a | 19.424.315.2 | 0.39±0.100.33±0.080.27±0.11b0.18±0.05bde0.22±0.09bd | 30.853.843.6 |
组别 | 剂量g/(kg·d) | n | 扭体反应次数(次) | 抑制率(%) |
对照组祛风息痛丸低剂量组祛风息痛丸中剂量组祛风息痛丸高剂量组追风透骨丸组 | 0.361.083.241.82 | 2020202020 | 47.8±21.435.4±14.7a34.7±17.1a29.8±17.5b30.1±19.9b | 25.927.437.737.0 |
组别 | 剂量g/(kg·d) | n | 药前痛阈(s) | 药后痛阈(s) |
对照组祛风息痛丸低剂量组祛风息痛丸中剂量组祛风息痛丸高剂量组追风透骨丸组 | 0.361.083.241.82 | 1010101010 | 21.0±6.520.7±5.021.1±2.520.3±4.919.4±5.4 | 20.7±5.428.6±6.3ag31.9±7.0bh39.3±9.9bdeh38.3±10.6bch |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100366945A CN100363033C (zh) | 2005-08-25 | 2005-08-25 | 一种治疗风寒湿痹症疼痛的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100366945A CN100363033C (zh) | 2005-08-25 | 2005-08-25 | 一种治疗风寒湿痹症疼痛的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1739678A true CN1739678A (zh) | 2006-03-01 |
CN100363033C CN100363033C (zh) | 2008-01-23 |
Family
ID=36092303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100366945A Expired - Fee Related CN100363033C (zh) | 2005-08-25 | 2005-08-25 | 一种治疗风寒湿痹症疼痛的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100363033C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104435335A (zh) * | 2014-12-18 | 2015-03-25 | 王富 | 一种治疗颈椎病、腰间盘病、乳腺增生病、风湿病的中药及制备方法 |
CN105079357A (zh) * | 2015-08-14 | 2015-11-25 | 牛林中 | 痹症外贴膏 |
CN105148042A (zh) * | 2015-10-05 | 2015-12-16 | 淄博齐鼎立专利信息咨询有限公司 | 一种治疗痹症的中药软膏 |
CN107661425A (zh) * | 2017-10-19 | 2018-02-06 | 贵州广济堂药业有限公司 | 一种消痛膏及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1186694A (zh) * | 1998-01-06 | 1998-07-08 | 李韶雪 | 愈痛膏及其制备方法 |
-
2005
- 2005-08-25 CN CNB2005100366945A patent/CN100363033C/zh not_active Expired - Fee Related
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104435335A (zh) * | 2014-12-18 | 2015-03-25 | 王富 | 一种治疗颈椎病、腰间盘病、乳腺增生病、风湿病的中药及制备方法 |
CN105079357A (zh) * | 2015-08-14 | 2015-11-25 | 牛林中 | 痹症外贴膏 |
CN105148042A (zh) * | 2015-10-05 | 2015-12-16 | 淄博齐鼎立专利信息咨询有限公司 | 一种治疗痹症的中药软膏 |
CN107661425A (zh) * | 2017-10-19 | 2018-02-06 | 贵州广济堂药业有限公司 | 一种消痛膏及其制备方法 |
CN107661425B (zh) * | 2017-10-19 | 2020-12-22 | 贵州广济堂药业有限公司 | 一种消痛膏及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN100363033C (zh) | 2008-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1302801C (zh) | 治疗子宫肌瘤的中药复方制剂 | |
CN102688420B (zh) | 一种治疗牛皮癣的中药汤剂 | |
CN1411830A (zh) | 治疗高血压的药物及其制备方法 | |
CN104666579A (zh) | 一种治疗膝关节滑膜炎的中药组合物及其制备方法 | |
CN1712054A (zh) | 秦川通痹片 | |
CN100363033C (zh) | 一种治疗风寒湿痹症疼痛的药物及其制备方法 | |
CN1742775A (zh) | 一种预防和治疗骨科疾病的药物组合物 | |
CN1840160A (zh) | 抗骨质增生粉 | |
CN102670977A (zh) | 一种治疗痹症的中药组合物及其制备方法和用途 | |
CN102247519A (zh) | 治疗类风湿性关节炎的中药配方 | |
CN1132616C (zh) | 一种治疗痹证病的中药 | |
CN102600432B (zh) | 一种治疗乳腺增生的中药 | |
CN1111036C (zh) | 治疗良性甲状腺肿的药物 | |
CN104189190B (zh) | 瘙痒性鹅掌风中药药浴及制备方法 | |
CN1772245A (zh) | 按摩推拿保健蛇药酒及其应用 | |
CN100363037C (zh) | 一种治疗风湿关节炎及跌打损伤疼痛的药物及其制备方法 | |
CN1203876C (zh) | 治疗产后子宫复旧不全病症的药物及制备方法 | |
CN104258275A (zh) | 一种用于治疗瘀血内结型良性卵巢肿瘤的中药组合物 | |
CN1840101A (zh) | 具有祛风除湿、通经络、散寒止痛功能的中药及制备工艺 | |
CN1927349A (zh) | 一种治疗痹症的中药及其制备方法 | |
CN102166305A (zh) | 一种治疗扁平苔癣的中药组合物及其制备方法 | |
CN1872165A (zh) | 一种药物组合物及其制备方法和质量控制方法 | |
CN107213250A (zh) | 一种用于防治类风湿关节炎的中药组合物及其制备方法 | |
CN1299748C (zh) | 一种减肥调理补气袋 | |
CN1861119B (zh) | 治疗风湿病的中药及其制法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PP01 | Preservation of patent right |
Effective date of registration: 20151222 Granted publication date: 20080123 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20161222 Granted publication date: 20080123 |
|
PP01 | Preservation of patent right |
Effective date of registration: 20161222 Granted publication date: 20080123 |
|
RINS | Preservation of patent right or utility model and its discharge | ||
PD01 | Discharge of preservation of patent | ||
PD01 | Discharge of preservation of patent |
Date of cancellation: 20201222 Granted publication date: 20080123 |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080123 Termination date: 20180825 |